H uman leucocyte class I antigens (HLA-I) are expressed on the surface of all nucleated cells but can also be found in soluble forms. These soluble HLA-I (sHLA-I) molecules can be produced by either membrane shedding, proteolysis of the intact heavy chain, or by alternative splicing. 1 They have been implicated in regulatory functions and have immunomodulatory properties. 2 Increased levels of sHLA-I were found during graft rejections, in various infectious (cytomegalovirus, hepatitis B or C, HIV infection, active tuberculosis) and autoimmune diseases. [3] [4] [5] [6] In systemic lupus erythematosus and rheumatoid arthritis, levels of sHLA-I antigens correlate with disease activity. 4 6 Spondyloarthropathies (SpA) are conditions closely linked to HLA-B27, a class I antigen. Thus, in this study, we evaluated the serum concentrations of sHLA-I antigens in a large cohort of patients with SpA.
One hundred and twenty three patients who met the European Spondylarthropathy Study Group criteria for SpA 7 were assessed (table 1). Disease activity was evaluated by the Bath Ankylosing Spondylitis Disease Activity Index and laboratory measures of inflammation (erythrocyte sedimentation rate and serum C reactive protein). The control group comprised 102 healthy subjects (63 male; mean (SD) age 39.5 (3.4)) and included 23 HLA-B27 positive subjects. Determination of sHLA-I antigens was done by a sandwich enzyme linked immunosorbent assay (ELISA; using W6/32 and an anti-b 2 -microglobulin polyclonal antibody; Bouty Laboratories, Milan, Italy).
Patients with SpA had decreased sHLA-I serum levels in comparison with healthy controls (mean (SD) 0.86 (0.6) v 1.18 (0.5) mg/ml; p = 0.0003) (fig 1) . HLA-B27 positive SpA showed decreased sHLA-I concentrations in comparison with HLA-B27 negative SpA (0.79 (0.26) v 1.17 (0.7) mg/ml; p = 0.007), while there was no difference between HLA-B27 positive and HLA-B27 negative controls (1.24 (0.5) v 1.17 (0.5) mg/ml; p.0.05). Furthermore, there was no significant difference in sHLA-I concentrations between HLA-B27 negative patients with SpA and HLA-B27 negative controls The significance and role of the sHLA-I antigens still remain unclear. They are present in several body fluids 8 and in synovial fluid from various arthropathies. 9 sHLA-I antigens can bind antigenic peptides and they probably have immunoregulatory functions by the inhibition of cytotoxic T lymphocytes and natural killer cells. 1 2 Previous studies have suggested that sHLA-I might be used as marker of disease activity or as prognostic factor in autoimmune diseases. 4 6 On the contrary, in our series of patients with SpA we observed decreased values of sHLA-I. These results were particularly evident in HLA-B27 positive patients with SpA while HLA-B27 did not influence the level of sHLA-I in controls. Thus, both the disease and the HLA-B27 antigen itself can explain this low production of sHLA-I. However, sHLA-I molecules could not be used as markers for the evaluation or for the follow up of these diseases. Different factors have been related to the production of sHLA-I antigens: genetic backgrounds, HLA-I haplotypes, treatments such as non-steroidal anti-inflammatory drugs. HLA-B27 can form heavy chain homodimers, 10 but it is not currently known whether these HLA-B27 homodimers might influence the release or production of sHLA-I. However, such a low level of serum sHLA-I in SpA may interfere with immune regulation or cytotoxic T lymphocyte and natural killer cell control, and this might contribute to the pathophysiology of the SpA. Further studies are required to evaluate the soluble forms of HLA-B27. 
